HighVista Strategies LLC Has $3.50 Million Stake in Celldex Therapeutics, Inc. $CLDX

HighVista Strategies LLC lifted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 26.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 135,258 shares of the biopharmaceutical company’s stock after buying an additional 28,705 shares during the quarter. HighVista Strategies LLC owned about 0.20% of Celldex Therapeutics worth $3,499,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares during the last quarter. Millennium Management LLC grew its position in shares of Celldex Therapeutics by 327.3% during the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock worth $7,259,000 after buying an additional 306,330 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock valued at $2,383,000 after acquiring an additional 14,979 shares during the period. Envestnet Asset Management Inc. bought a new position in Celldex Therapeutics during the 2nd quarter worth approximately $861,000. Finally, Geode Capital Management LLC grew its holdings in Celldex Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 1,672,980 shares of the biopharmaceutical company’s stock valued at $34,050,000 after purchasing an additional 83,174 shares during the period.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $29.51 on Monday. The stock has a market cap of $1.96 billion, a P/E ratio of -7.59 and a beta of 1.17. The company has a fifty day moving average price of $26.34 and a two-hundred day moving average price of $26.01. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $31.99.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%. As a group, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CLDX has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. The Goldman Sachs Group increased their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. Finally, Barclays raised their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $44.50.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.